Home Pharmaceuticals Brain Ischemia Market Size, Share, Trends Growth Analysis Forecast 2031

Brain Ischemia Market

Brain Ischemia Market Size, Share & Trends Analysis Report By Condition Type (Focal Brain Ischemia, Global Brain Ischemia), By Treatment (Angioplasty, Beta Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, Others), By End-User (Hospitals and Clinics, Research and Academic Institutes, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRPH55782DR
Study Period 2019-2031 CAGR 7.6%
Historical Period 2019-2021 Forecast Period 2023-2031
Base Year 2022 Base Year Market Size USD 780 Million
Forecast Year 2031 Forecast Year Market Size USD 1510 Million
Largest Market North America Fastest Growing Market Europe
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

The global brain ischemia market revenue was valued at USD 780 million in 2022. It is estimated to reach USD 1510 million by 2031, growing at a CAGR of 7.6% over the forecast period (2023–2031)

The global brain ischemia market is primarily boosted by the surging prevalence of cerebrovascular diseases like stroke, TIA, carotid artery disease, etc., and risk factors like hypertension, diabetes, and obesity, among others, which increase the chance of brain ischemia. Moreover, the growth in the geriatric population is also increasing the cases of brain ischemia, which is augmenting the market expansion globally.

Brain ischemia, also called cerebral ischemia, is a disease marked by inadequate blood supply to the brain, which lowers the amount of oxygen and nutrients that are available to brain cells. The absence of sufficient blood circulation can cause harm to the brain tissue and, if it is intense or chronic, can give rise to significant neurological disorders. Brain ischemia, characterized by insufficient oxygen and nutrients, triggers a series of events, including the production of inflammatory substances, exacerbating the harm inflicted on brain cells.

The extent of brain ischemia directly influences the magnitude of harm and the consequent symptoms. Brain ischemia can be linked to conditions such as stroke, transient ischemic attack (TIA or "mini-stroke"), and vascular dementia. It is critical to identify and treat conditions that cause cerebral ischemia as soon as possible to minimize damage and prevent long-term complications. Treatment options may include pharmacotherapy, surgical procedures, or alternative interventions to reinstate adequate blood circulation and mitigate the likelihood of repeat episodes.

Market Dynamics

Global Brain Ischemia Market Drivers:

Rising Prevalence of Cerebrovascular Diseases and Risk Factors 

The rising incidence of cerebrovascular illnesses, including stroke, transient ischemic attack (TIA), and carotid artery disease, is a significant factor driving the brain ischemia market. These conditions are the primary contributors to the occurrence of brain ischemia. Stroke is the second most common cause of death and the primary cause of disability globally, as stated by the World Health Organization (WHO). Moreover, as stated by the CDC, ischemic stroke comprises around 87% of the total number of strokes.

Furthermore, there is a global increase in the prevalence of risk factors associated with cerebrovascular illnesses, including hypertension, diabetes, obesity, smoking, and aging. These variables are contributing to a higher occurrence of brain ischemia. Specifically, the worldwide occurrence of hypertension was approximated to be 26.4% in 2000 and is projected to rise to 29.2% by 2025. Hence, the increasing prevalence of cerebrovascular illnesses and their associated risk factors is anticipated to drive the demand for brain ischemia detection and treatment in the foreseeable future.

Growing Geriatric Population

The elderly population is more prone to disorders such as strokes and cerebral vascular diseases. The geriatric population worldwide is proliferating due to the remarkable increase in life expectancies and easy access to medical innovations. The United Nations estimated in 2020 that the global population aged 65 or older in 2019 was approximately 727 million, accounting for 9.3 percent of the total global population. It is anticipated to exceed 1.5 billion by 2050, making up 16.0 percent of the global population.

Additionally, the disease burden imposed by geriatric patients is the highest due to the effects of aging and an unhealthy lifestyle. The economic influence of the geriatric population is much greater in developed nations than in emerging nations. Therefore, the anticipated increase in the global population aging will presumably lead to a corresponding rise in the demand for treatments for brain ischemia.

Global Brain Ischemia Market Restraint:

Lack of Awareness 

A significant limitation in the brain ischemia market is the insufficient awareness and understanding of the signs and symptoms of brain ischemia among both the general population and healthcare professionals. This can lead to delays in diagnosing and treating the illness. Brain ischemia is a critical medical condition that necessitates prompt attention and action to avert irreparable brain damage and mortality. Nevertheless, a significant number of individuals fail to acknowledge the indicators that indicate cerebral ischemia.

Furthermore, certain healthcare practitioners may need more expertise and resources to swiftly and effectively identify and treat brain ischemia, particularly in low- and middle-income countries with limited access to high-quality and cheap healthcare services. Hence, the limited understanding and awareness regarding brain ischemia provide a significant obstacle to the market's expansion.

Global Brain Ischemia Market Opportunities:

Advancement in Diagnostic and Therapeutic Modalities

In recent years, there has been significant growth in the advancement of new and effective diagnostic and therapeutic methods for brain ischemia, thanks to the progress in technology and creativity in the field of neurology. Using artificial intelligence (AI) and machine learning (ML) has facilitated enhanced image analysis, risk prognosis, medical intervention, and clinical decision-making assistance for patients suffering from brain ischemia. For instance, Brainomix's e-Stroke platform, created by the UK-based company Brainomix, uses artificial intelligence to analyze CT and MRI scans automatically. It then notifies doctors about patients who can potentially benefit from mechanical thrombectomy.

Additionally, it facilitates the connection between specialists in various hospitals by rapidly analyzing results in under two minutes and transmitting data to hospital systems and even doctors' smartphones. The Oxford Academic Health Science Network's analysis revealed that hospitals utilizing Brainomix's e-Stroke artificial intelligence (AI) platform witnessed a remarkable increase of over 55% in inpatient treatment rates. Moreover, developing novel equipment and procedures, such as mechanical thrombectomy, carotid artery stenting, and neurostimulation, has improved the effectiveness and safety of therapies for brain ischemia. This is anticipated to create new opportunities and cures for managing brain ischemia soon.

Regional Analysis

North America Dominates the Global Market

Based on region, the global brain ischemia market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. 

North America is the most significant market shareholder and is expected to expand substantially during the forecast period. The dominance of this region can be ascribed to the increased occurrence of cerebrovascular illnesses and their associated risk factors, including hypertension, diabetes, obesity, and smoking, particularly in the United States and Canada. According to the CDC, stroke was responsible for 16.7% of all deaths caused by cardiovascular disease in 2021. A stroke occurs in the United States at a rate of one every 40 seconds. Stroke causes the death of two individuals every 3 minutes and 14 seconds. Moreover, the United States experiences an annual incidence of strokes, affecting about 795,000 individuals.

Furthermore, as per the CDC, approximately 11.5% of individuals aged 18 or above in the United States engaged in cigarette smoking in 2021. About 28.3 million adults in the United States currently participate in cigarette smoking. A smoking-related disease affects more than 16 million Americans. Therefore, the significant occurrence of smoking is expected to propel the brain ischemia market in the region. Moreover, favorable reimbursement policies, a firmly established healthcare infrastructure, and prominent pharmaceutical and medical device manufacturers are anticipated to expedite market expansion in this region.

Europe is expected to become the second-largest market for brain ischemia due to the rising prevalence of stroke and TIA, together with the aging population, particularly in Germany, France, and the UK. As per Eurostat, the proportion of people aged 65 or over in the EU population in 2022 was 21.1%. Similarly, the increasing investment and cooperation in research and development and the use of cutting-edge technologies and devices are anticipated to bolster market expansion in this region. Moreover, using artificial intelligence (AI) in medical imaging devices to improve and advance imaging procedures further propels market growth. For instance, in December 2023, AiOne Healthcare Technologies Ltd., a company based in the United Kingdom, announced a strategic agreement with DeepTek.ai. This partnership aims to introduce DeepTek's advanced skills in managing and processing medical AI images to the U.K. market.

The Asia-Pacific region is expected to experience the fastest growth in the brain ischemia market. This is due to the rapid advancement and enhancement of healthcare infrastructure, the increasing awareness and demand for neurological care, and the rising disposable income and healthcare spending in countries such as China, India, and Japan. Moreover, a substantial number of patients and a significant untapped market potential in this area is anticipated to provide profitable prospects for the market participants.

Furthermore, the leading players have implemented strategic initiatives to increase their regional market share. For instance, in September 2023, Pharmazz, a biopharmaceutical startup, and Sun Pharmaceutical Industries entered a licensing deal to distribute Tyvalzi (Sovateltide) in India. Pharmazz has created a groundbreaking medication specifically designed to address cerebral ischemic stroke. Sun Pharma has obtained marketing authorization for Sovateltide in the country, which will be marketed under the trade name Tyvalzi. The drug can be used within a 24-hour window after the appearance of symptoms. These factors contribute to the growth of the Asia-Pacific market.

Report Scope

Report Metric Details
Segmentations
By Condition Type
  1. Focal Brain Ischemia
  2. Global Brain Ischemia
By Treatment
  1. Angioplasty
  2. Beta Blockers
  3. Angiotensin-Converting Enzyme (ACE) Inhibitors
  4. Others
By End-User
  1. Hospitals and Clinics
  2. Research and Academic Institutes
  3. Others
Company Profiles Taxus Cardium Pharmaceuticals Group (CRXM) Boston Scientific Corporation Merck KGaA Cook Edwards Lifesciences Corporation Novartis AG Abbott BD. Johnson & Johnson Private Limited Boehringer Ingelheim International GmbH. Bayer AG H. Lundbeck A/S Bristol-Myers Squibb Company AstraZeneca
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Singapore Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

The global brain ischemia market is bifurcated into condition type, treatment, and end-user.

Based on the condition type, the global brain ischemia market is segmented into focal brain ischemia and global brain ischemia. 

Focal brain ischemia is characterized by an insufficient or specific decrease in blood flow to a particular brain area. Focal brain ischemia typically arises from the blockage or obstruction of a brain blood artery that provides blood to a specific brain area. The obstruction might occur from a blood clot, atherosclerosis, or other vascular illnesses. Brain cells may sustain damage or perish if they do not receive sufficient nutrients and oxygen when there is a disruption in blood flow to the affected location. In comparison to global brain ischemia, which is typically brought on by cardiac arrest or severe hypotension, focal brain ischemia, such as ischemic stroke and TIA, has a higher prevalence and incidence, resulting in substantial segment growth.

Based on treatment, the global brain ischemia market is bifurcated into angioplasty, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and others. 

Angioplasty is a medical intervention to address constricted or obstructed blood vessels, typically arteries. The phrase "angioplasty" is a combination of the terms "angio," which refers to a vessel, and "plasty," which means to repair or reshape. Angioplasty involves inserting a catheter, a slender and flexible tube, into a restricted or blocked artery. The catheter's tip is fitted with a deflated balloon. The catheter is commonly inserted into the blood vessels through a minor surgical cut, usually in the groin or wrist, and directed to the obstruction's location with medical imaging methods like fluoroscopy.

Upon reaching the intended location, the catheter inflates the balloon, exerts pressure on the plaque against the artery's walls, and expands the blood vessel. This procedure facilitates the reestablishment of blood circulation to the impacted region. A small mesh tube, known as a stent, may be inserted into the obstructed artery in certain instances to maintain its integrity.

Based on end-users, the global brain ischemia market is bifurcated into hospitals and clinics, research and academic institutes, and others. 

The hospital and clinic segment is the highest shareholder. The primary reason for the dominance of this segment is the increased number of brain ischemia patients who are seeking diagnosis and treatment in hospitals and clinics. Additionally, advanced facilities and equipment in these settings contribute to this trend. Moreover, the surging number of hospitals and clinics across several countries positively impacts the segment growth. For example, as per the American Hospital Association Annual Survey 2021, in the United States, there were 1,805 rural community hospitals, 3,336 urban community hospitals, and 3,453 community hospitals in a system in 2019. Moreover, total admissions in all United States hospitals were around 36,241,815 in 2019.

Market Size By Condition Type

Market Size By Condition Type
  • Focal Brain Ischemia
  • Global Brain Ischemia
  • Recent Developments

    • July 2023- Aidoc, an industry leader in clinical artificial intelligence, unveiled its revolutionary Full Brain Solution today. This novel resolution will effectively broaden the anatomical scope that AI examines to detect potential strokes, enabling the detection and management of patients afflicted with medium vessel occlusions (MeVOs) and large vessel occlusions posterior and anterior to the vessel.
    • July 2023- Hyperfine, Inc. (Nasdaq: HYPR), a pioneering medical device company that developed the Swoop® system, the first portable magnetic resonance brain imaging system to receive FDA clearance, declared the initiation of an international, multi-site observational study called ACTION PMR (ACuTe Ischemic strOke detectioN with Portable MR).

    Top Key Players

    Brain Ischemia Market Share of Key Players

    Brain Ischemia Market Share of Key Players
    Taxus Cardium Pharmaceuticals Group (CRXM) Boston Scientific Corporation Merck KGaA Cook Edwards Lifesciences Corporation Novartis AG Abbott BD. Johnson & Johnson Private Limited Boehringer Ingelheim International GmbH. Bayer AG H. Lundbeck A/S Bristol-Myers Squibb Company AstraZeneca Others

    Frequently Asked Questions (FAQs)

    How big is the Global market?
    The global brain ischemia market revenue was valued at USD 780 million in 2022. It is estimated to reach USD 1510 million by 2031, growing at a CAGR of 7.6% over the forecast period (2023–2031)
    North America has the highest growth in the global market.
    Key verticals adopting the market include: Taxus Cardium Pharmaceuticals Group (CRXM), Boston Scientific Corporation, Merck KGaA, Cook, Edwards Lifesciences Corporation, Novartis AG, Abbott, BD., Johnson & Johnson Private Limited, Boehringer Ingelheim International GmbH., Bayer AG, H. Lundbeck A/S, Bristol-Myers Squibb Company, AstraZeneca
    Growing Geriatric Population is the key driver for the growth of the global market.
    Advancement in Diagnostic and Therapeutic Modalities is one of the upcoming key trends in the global market.


    We are featured on :